Ocugen (OCGN) Enterprise Value (2019 - 2026)
Ocugen's (OCGN) quarterly Enterprise Value came in at -$37.8 million in Q1 2025, down 43.32% YoY from -$66.7 million in Q1 2024, and down 140.81% on a QoQ basis from -$15.7 million in Q2 2024.
Analysis
Ocugen (OCGN) Enterprise Value (2019 - 2026) Analysis & Trends
Ocugen (OCGN) has 12 years of Enterprise Value data on file, last reported at -$37.8 million in Q1 2025.
- Quarterly Enterprise Value fell 43.32% year-over-year to -$37.8 million in Q1 2025, while the trailing twelve-month figure through Mar 2025 was -$37.8 million (down 43.32% YoY) and the FY2023 annual result came in at -$39.5 million, up 56.6% from the prior year.
- Enterprise Value slipped to -$37.8 million in Q1 2025, from -$15.7 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$15.7 million in Q2 2024 to a low of -$129.8 million in Q1 2022.
- A 5-year average of -$75.7 million and a median of -$76.7 million in 2023 frame the typical range for Enterprise Value.
- Annual changes were most pronounced in 2021 — Enterprise Value slumped 1459.04% — and 2024, when it jumped 77.76%.
- Tracing OCGN's Enterprise Value over 5 years: stood at -$95.0 million in 2021, then climbed by 4.24% to -$90.9 million in 2022, then jumped by 56.6% to -$39.5 million in 2023, then soared by 60.22% to -$15.7 million in 2024, then slumped by 140.81% to -$37.8 million in 2025.
- The last three Enterprise Value figures came in at -$37.8 million (Q1 2025), -$15.7 million (Q2 2024), and -$26.4 million (Q1 2024), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Ocugen | 458.91 Mn | 358.81 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 418.64 Mn |
| Mar 31, 2026 | 612.36 Mn |
| Dec 31, 2025 | 403.14 Mn |
| Sep 30, 2025 | 509.08 Mn |
| Jun 30, 2025 | 256.53 Mn |
| Mar 31, 2025 | 168.46 Mn |
| Dec 31, 2024 | 234.55 Mn |
| Sep 30, 2024 | 288.00 Mn |
| Jun 30, 2024 | 383.31 Mn |
| Mar 31, 2024 | 395.61 Mn |
| Dec 31, 2023 | 108.06 Mn |
| Sep 30, 2023 | 49.12 Mn |
| Jun 30, 2023 | 68.72 Mn |
| Mar 31, 2023 | 160.63 Mn |
| Dec 31, 2022 | 197.15 Mn |
| Sep 30, 2022 | 284.10 Mn |
| Jun 30, 2022 | 375.65 Mn |
| Mar 31, 2022 | 581.81 Mn |
| Dec 31, 2021 | 812.22 Mn |
| Sep 30, 2021 | 1.32 Bn |